Tin Kyaw Kyaw Aung

Tin Kyaw Kyaw Aung

Auto-generated profile, based on publicly available information

Tin Kyaw Kyaw Aung

Department of General Medicine, Sengkang General Hospital, Singapore

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Osteoporosis and Sarcopenia
Verified
Journal Article
Open access
MCManju Chandran
Manju Chandran
YCYun Ann Chin
Yun Ann Chin
KCKuan Swen Choo
Kuan Swen Choo
WAWan Chen Ang
Wan Chen Ang
XHXiao Feng Huang
Xiao Feng Huang
YHYing Hao
Ying Hao
The accuracy of FRAX® as a screening tool to identify osteoporosis and how it compares with tools such as Osteoporosis Self-Assessment Tool for Asians (OSTA), in Southeast Asian women has so far been unexplored. We aimed to determine the FRAX® thresholds that accurately identify densitometric osteoporosis and to compare its performance with that of OSTA for this purpose. Singaporean postmenopausal women (n = 1056) were evaluated. FRAX® Major Osteoporotic Fracture Probability (MOFP), Hip Fracture Probability (HFP) scores, and OSTA indices were calculated. Receiver operating characteristic (ROC) curves were constructed and via the Youden index, the optimal cut-off points of balanced sensitivity and specificity for dual energy X-ray absorptiometry (DXA)-defined osteoporosis were identified and the performance characteristics were compared. A FRAX® MOFP threshold of ≥3.7% had sensitivity, specificity, positive predictive value and negative predictive value of 0.78 (0.73–0.83), 0.63 (0.59–0.66), 0.4 (0.36–0.44), and 0.9 (0.87–0.92), respectively in identifying osteoporosis. The corresponding values for a HFP threshold of ≥0.6% were 0.85 (0.80–0.89), 0.58 (0.55–0.62), 0.39 (0.35–0.43), and 0.92 (0.9–0.94) and that for an OSTA index cut-off of ≤ −1.2 were 0.76 (0.70–0.81), 0.74 (0.71–0.77), 0.48 (0.43–0.54), and 0.91 (0.88–0.93). The area under the ROC curves were 82.8% (79.9%–85.6%), 77.6% (74.2%–81%), and 79.6% (76.5%–82.8%) for OSTA, MOFP, and HFP thresholds respectively. FRAX® and OSTA perform comparably in identifying osteoporosis in our population. OSTA has only 2 parameters and may be simpler to use. However, FRAX® may also have a role in primary screening to identify the postmenopausal woman to be referred for DXA scanning and may help facilitate fracture risk reduction discussions with the patient.

1 June 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
FLFaidra Laskou
Faidra Laskou
TAT. Aung
T. Aung
DGD. Gayford
D. Gayford
SBS. Banerjee
S. Banerjee
CCC.S. Crowson
C.S. Crowson
BDB. Dasgupta
B. Dasgupta
Background The dreaded complication of giant cell arteritis (GCA), irreversible sight loss (SL), is present in 15%–25% of patients at diagnosis. This is likely due to delayed presentation, recognition and treatment. Fast track pathways for urgent assessment of suspected GCA reduce SL with associated cost savings. Information regarding the burden of SL in GCA is required to guide health strategy and has been explored in this UK wide study. Methods This is a prospective observational multi-centre study of visual involvement attributable to GCA. Demographic, disease features and treatment information was collected on all patients with new or relapsing GCA with or without visual symptoms (VS) or SL.SL was defined as symptomatic loss of acuity, field of vision or diplopia ascribable to ischaemic complications of GCA. Patients with transient VS were not considered to have SL. Analyses were performed using chi-squared and rank sum tests. Results Patients were predominantly female (274/388) and Caucasian; 3 non-Caucasian(Asian British, Black/Afro-Caribbean and Turkish).VS were present in 135/388 patients (35%) from 19 UK sites. Of patients with VS, these were transient or intermittent SL (n=9,7%), diplopia (n=33,24%), blurred vision (n=17,13%), flashing lights (n=4,3%) and eye pain (n=7,5%). Transient or permanent loss of acuity occurred in 92 patients (48 anterior ischaemic optic neuropathy [AION], 6 central retinal artery occlusion [CRAO],1 posterior ischaemic optic neuropathy, all attributed to GCA);1 hemispheric retinal vein occlusion, 1 branch retinal artery occlusion, 1 peri-papillary haemorrhage, 1 vitelliform dystrophy macula.8 had oculomotor nerve palsies(NP)(1 bilateral 3rd,1 bilateral 6th and 6 unilateral 3rd or 6th NP). Patients with VS were older than those without(mean ±SD age 75.9±9.3 and 73.5±8.5 respectively, p<0.001). Patients with VS had less headaches (p=0.012) and scalp tenderness (p=0.05) but more frequently tongue claudication (p=0.014), shorter symptom duration (3.9±5.5 days, p=0.001), lower CRP although not statistically significant(p=0.059), were less likely to meet ACR criteria and to improve than those without VS (p<0.001). No association was found with comorbidities or deprivation index.SL in 54 (40%) patients was due to AION or CRAO. Transient CRAO or AION was described in 17 and 30/47 (64%) had permanent SL (data missing from 7 patients). Patients with AION/CRAO were older (80.9±6.7 years) than those without AION/CRAO (73.3±8.7 years, p<0.001). They had shorter symptom duration (4.2±7.0 days, p=0.024), less likely to improve than those without AION/CRAO (p<0.001), less likely to have headaches (p<0.001) or polymyalgic symptoms (p=0.002), and more likely to have jaw claudication (p=0.043) and hypertension (p=0.002). Only 7 had diplopia on presentation. 5 patients experienced AION as manifestation of recrudescing disease. Conclusions VS often leading to SL in GCA requires urgent management. Patients with VS were older, without ‘typical symptoms’ such as headache and polymyalgia but more likely to have ischaemic symptoms such as jaw and tongue pain and hypertension. Recognition of VS associated features should be embodied in public and professional awareness programs to prevent permanent SL in GCA. Disclosure of Interest None declared

1 June 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
FLFaidra Laskou
Faidra Laskou
FCF. Coath
F. Coath
SMS. Mackie
S. Mackie
SBS. Banerjee
S. Banerjee
TAT. Aung
T. Aung
BDB. Dasgupta
B. Dasgupta
Background Diagnosis of Giant Cell Arteritis(GCA) is difficult since its manifestations are protean1. Under-diagnosis is associated with ischaemic complications whereas over diagnosis is associated with inappropriate glucocorticoids (GC)2.GCA is diagnosed by different specialties, including family physicians, who would benefit from a clinical prediction score.A fast track pathway also requires clinical triage in terms of probability of disease. We evaluated all referred patients (08/16–08/17) to develop a pre-test probability score(PTBS) to support a diagnostic pathway and decision-making. Methods The PTBS was generated from long standing clinical experience. Information collected at initial assessment was given varying positive weightage. This included baseline demographics (age-gender), symptomatology at presentation(onset, headache and scalp tenderness, ischaemic symptoms, constitutional symptoms, polymyalgia),C-Reactive protein(CRP) and examination findings(ischaemic ophthalmic complications, temporal artery abnormalities, extra-cranial abnormalities, cranial nerve palsies). Negative weightage was given for competing diagnoses (infection, cancer, head and neck pathology, systemic rheumatological diseases). The PTBS was compared with the final diagnosis as GCA or non-GCA 6 months after the initial assessment. Analysis was performed in Stata SE, version 13.1. Results 122 PTBS were collected of which CRP was missing in 1 case which was excluded from the analysis.23 had a final diagnosis of GCA at 6 months follow up. The rest consist our control group(99 patients). The area under the ROC curve for the 121 cases was 0.953 (figure 1). Using the bootstrap method gave an estimated area under the ROC curve (95% confidence interval) of 0.953 (0.911, 0.994). At the point of inflection, corresponding to a cut point of 9.5, sensitivity was 95.7%, and specificity was 86.7%;the likelihood ratio for a positive test was 7.2 and the likelihood ratio for a negative test, 0.050. At this cut point, 88.4% cases were correctly classified. Conclusions This single centre retrospective study suggests that PTBS is a useful standardised assessment tool for rating pre-test probability for GCA with high levels of sensitivity and specificity. PTBS may reduce variation in clinical assessment and aid decision making.A patient with low probability score(<9.5) can be managed with colour doppler ultrasound examination(US) which if negative will exclude the disease and the clinician can reassure patient.A patient with high PTBS and positive US can safely have the diagnosis confirmed and treated with GC. With intermediate scores, conflicting PTBS and US findings, equivocal US, additional investigations including TA biopsy and/or other imaging scans may be needed. Our results need validation in a prospective study and in internal and external validation cohorts. PTBS has the potential for forming the basis for education programme for the correct and early diagnosis of GCA and limit inappropriate GC in non GCA mimics. References [1] Murchison AP, et al. Validity of the American College of Rheumatology Criteria for the Diagnosis of Giant Cell Arteritis.Am J Ophthalmol2012Oct;154(4):722–9. [2] Elsideeg S, et al. SAT0293 Association between Clinical Presentation and Blindness in Gca and Effects of Gca-Related Visual Loss on Morbidity, Mortality and Quality of Life. Ann Rheum Dis2014Jun;73(Suppl 2):699.1–699. Disclosure of Interest None declared

1 November 2021 in The American Journal of Medicine
Verified
Journal Article
Closed access
TATin Kyaw Kyaw Aung
Tin Kyaw Kyaw Aung
TCTyng Yu Chuah
Tyng Yu Chuah
MCMarvin Wei Jie Chua
Marvin Wei Jie Chua

1 April 2021 in The American Journal of Medicine
Verified
Journal Article
Closed access
BCBingfeng Matthew Chuah
Bingfeng Matthew Chuah
TATin Kyaw Kyaw Aung
Tin Kyaw Kyaw Aung
SWSteven Bak Siew Wong
Steven Bak Siew Wong
KYKok Pin Yong
Kok Pin Yong